IN BRIEF: Aptamer raises PS2 million for Optimer commercialisation
Aptamer Group PLC - York, England-based biotechnology firm that provides Optimer binders for use in therapeutics, diagnostics, bioprocessing and research - Raises £2.0 million from placing of 666.7 million new shares at 0.3 pence. Part of the equity raise is conditional on shareholder approval at a general meeting called for July 24. Chair Adam Hargreaves invests £100,000 in the equity raise, putting his stake at 6.4%. Aptamer says it will use the fresh funds to ‘accelerate the commercialisation of its Optimer technology, further develop its intellectual property portfolio, and advance its licensing pipeline.’
On Monday, Aptamer announced a ‘significant milestone’ in its liver fibrosis programme. It said it identified and validated a novel molecular target for its Optimer delivery platform. This could deliver targeted gene therapy to the specific liver cells that drive scarring, Aptamer said, increasing the commercial attractiveness of the platform.
On Friday last week, Aptamer said it signed a development and licensing agreement with ‘an established global company in the life sciences and diagnostics sector, part of a major multinational conglomerate’. Under the agreement, Aptamer will use its Optimer-Fc platform to develop a custom reagent for use in immunohistochemistry assays and diagnostic kits.
Current stock price: 0.39p
12-month change: down 44%
Copyright 2025 Alliance News Ltd. All Rights Reserved.